Condition (MeSH)
Eye Infections, Viral
ClinicalTrials.gov lists 94 trials for Eye Infections, Viral or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 21.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
2 of the 94 trials are tagged with Eye Infections, Viral itself; the rest are tagged with a narrower condition beneath it.
When did Eye Infections, Viral trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 2 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 2 |
Showing 10 of 25 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 94 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Eye Infections, Viral trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 10 |
| Phase 1/2 | 1 |
| Phase 2 | 12 |
| Phase 2/3 | 3 |
| Phase 3 | 12 |
| Phase 4 | 6 |
| Not applicable | 32 |
| Observational | 18 |
How many Eye Infections, Viral trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Completed | 76 |
| Terminated | 2 |
| Withdrawn | 4 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Eye Infections, Viral trials? (11)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 21 |
| Hoffmann-La Roche | 9 |
| National Eye Institute (NEI) | 5 |
| NicOx | 5 |
| Astra USA | 4 |
Showing 5 of 11 sponsors.
Which drugs are being tested for Eye Infections, Viral? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Ganciclovir | 31 |
| Foscarnet | 13 |
| Cidofovir | 9 |
| Probenecid | 5 |
| Sevirumab | 4 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Acyclovir 5% | 4 |
| Valganciclovir | 3 |
| Sagramostim | 2 |
| Anti-Rejection Agents | 1 |
| Valacyclovir arrow | 1 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Eye Infections, Viral trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Opportunistic Infection | 133 | 1 |
| Neutropenia | 124 | 1 |
| Thrombocytopenia | 37 | 1 |
| Proteinuria 2+ | 24 | 1 |
| COVID-19 Infection | 4 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Eye Infections, Viral? (34)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Multiple Anterior Chamber Paracenteses May Be Needed to Identify Cytomegalovirus Anterior Uveitis. | American journal of ophthalmology | 2025 | Yes |
| Aqueous humour concentration of topically applied 2.0% ganciclovir eye drops in eyes with cytomegalovirus anterior uveitis and endotheliitis. | Clinical & experimental ophthalmology | 2025 | Yes |
| Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus: The Zoster Eye Disease Randomized Clinical Trial. | JAMA ophthalmology | 2025 | Yes |
| The Effect of Metagenomic Sequencing on Patient Clinical Outcomes for Intraocular Infections: A Multicenter Randomized Controlled Trial. | American journal of ophthalmology | 2025 | Yes |
| CMV-Related Anterior Uveitis in a Mediterranean European Population: Clinical Features, Prognosis, and Long-Term Treatment Outcomes. | Ocular immunology and inflammation | 2024 | Yes |
Showing 5 of 34 publications.
Sub-conditions in MeSH (4)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.